To assess the efficacy and safety of aripiprazole versus placebo as adjunctive treatment to standard antidepressant therapy ( ADT ) in patients with major depressive disorder ( MDD ) who showed an incomplete response to 1 prospective and 1 to 3 historical courses of ADT within the current episode .
